Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Up – Here’s What Happened

Daiichi Sankyo Co., Ltd. – Sponsored ADR (OTCMKTS:DSNKY)’s stock price gapped up before the market opened on Wednesday . The stock had previously closed at $17.89, but opened at $18.4350. Daiichi Sankyo shares last traded at $18.2075, with a volume of 8,958 shares.

Analysts Set New Price Targets

A number of research firms recently weighed in on DSNKY. Zacks Research downgraded shares of Daiichi Sankyo from a “hold” rating to a “strong sell” rating in a research note on Monday, August 3rd. Jefferies Financial Group cut shares of Daiichi Sankyo from a “buy” rating to a “hold” rating in a research note on Thursday, July 30th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce”.

Daiichi Sankyo Trading Down 0.3%

The business’s 50-day moving average price is $17.01 and its two-hundred day moving average price is $17.37. The company has a market capitalization of $33.79 billion, a P/E ratio of 21.09, a PEG ratio of 3.28 and a beta of -0.18. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.42 and a quick ratio of 1.64.

Daiichi Sankyo (OTCMKTS:DSNKY) last released its quarterly earnings data on Friday, July 31st. The company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). The firm had revenue of $3.61 billion during the quarter, compared to the consensus estimate of $3.32 billion. Daiichi Sankyo had a net margin of 10.92% and a return on equity of 14.22%. Daiichi Sankyo has set its FY 2026 guidance at 0.870-0.870 EPS. As a group, analysts forecast that Daiichi Sankyo Co., Ltd. – Sponsored ADR will post 0.93 EPS for the current fiscal year.

About Daiichi Sankyo

Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.

Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.